AMENDMENT NO.4 TO LICENSING AND ASSIGNMENT AGREEMENT
Exhibit 10.7
AMENDMENT NO.4
TO LICENSING AND ASSIGNMENT AGREEMENT
This Amendment No.4 (“Amendment No.4”) to the Licensing and Assignment Agreement by and between Satsuma Pharmaceuticals, Inc. (“Company”) and Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) of June 30, 2016 (the “Agreement”) is dated as of May 25, 2020 (“Amendment No.4 Effective Date”).
|
|
A. |
Company and SNBL have previously entered into the Agreement, as well as AMENDMENT NO.1 TO LICENSING AND ASSIGNMENT AGREEMENT effective as January 13, 2017, AMENDMENT NO.2 TO LICENSING AND ASSIGNMENT AGREEMENT effective as of April 27, 2017, and AMENDMENT NO.3 TO LICENSING AND ASSIGNMENT AGREEMENT effective as of October 6, 2017. |
|
|
B. |
Company and SNBL desire that Exhibit 1.20.2 of the Agreement be amended and restated in its entirety and all other terms and conditions of the Agreement remain in full force and effect. |
For good and valuable consideration, Company and SNBL hereby agree as follows:
|
|
1. |
Amendment to the Agreement. |
|
|
a. |
Exhibit 1.20.2 is hereby amended and replaced in its entirety with the following: |
|
Exhibit 1.20.2 |
|||
|
|
|||
|
[Transnasal Composition Having Immediate Action and High Absorbability |
|||
|
Title |
Country |
Application No. (Date) |
Patent No. (Date) |
|
Transnasal Composition Having Immediate Action and High Absorbability |
JP |
2006-531575 (2005.08.05) |
4922762 (2012.02.10) |
|
US |
11/660,131 (2005.08.05) |
8,673,360 (2014.03.18) |
|
|
|
|
Priority Date: 2004.08.10 |
|
|
Preparation for Transnasal Application |
|||
|
Title |
Country |
Application No. (Date) |
Patent No. (Date) |
|
Preparation for Transnasal Application |
JP |
2008-551108 (2007.12.25) |
5415769 (2013.11.22) |
|
JP |
2013-209951 (2007.12.25) |
- |
|
|
US |
12/521,116 (2010.3.25) |
8,337,817 (2012.12.25) |
|
|
US |
13/649,515 (2012.10.11) |
10,195,139 (2019.02.05) |
|
|
EP (validated in UK, FR, DE, ES, IT) |
07860016.0 (2007.12.25) |
2116264 (2017.09.27) |
|
|
HK |
10108585.2 (2007.12.25) |
1142001B (2013.09.06) |
|
|
CN |
780051041.1 (2007.12.25) |
200780051041.1 (2013.04.24) |
|
|
Priority Date: 2006.12.26 |
|||
|
Intranasal Pharmaceutical Compositions with Improved Pharmacokinetics |
|||
|
Title |
Country |
Application No. (Date) |
Patent No. (Date) |
|
Intranasal Pharmaceutical Compositions with Improved Pharmacokinetics |
US |
12/780,433 (2010.05.14) |
9,101,539 (2015.08.11) |
|
EP |
10774745.3 (2010.05.14) |
- |
|
|
Priority Date: 2009.05.15 |
|||
|
Intranasal Granisetron and Nasal Applicator |
|||
|
Title |
Country |
Application No. (Date) |
Patent No. (Date) |
|
Intranasal Granisetron and Nasal Applicator |
US |
12/848,850 (2010.08.02) |
8,827,946 (2014.09.09) |
|
Priority Date: 2009.07.31 |
|||
|
Intranasal Delivery Devices |
|||
|
Title |
Country |
Application No. (Date) |
Patent No. (Date) |
|
Intranasal Delivery Devices |
US |
||
|
JP |
2013-551173 (2012.01.31) |
5960726 (2016.07.01) |
|
|
AU |
2012212866 (2012.01.31) |
2012212866 (2017.01.05) |
|
|
CA |
2825541 (2012.01.31) |
(Allowed 2020.01.10) |
|
|
CN |
201280016126.7 |
ZL 2012800161267 (2016.11.30) |
|
|
EP (GB, DE, FR, ES, IT) |
12742112.1 (2012.01.31) |
EP2670462 (2017.11.22) |
|
|
IN |
6718/DELNP/2013 |
- |
|
|
KR |
00-0000-0000000 |
|
|
|
RU |
2013140383 (2012.01.31) |
2594244 (2016.08.10) |
|
Page 2of 4
US-DOCS\116938752.2
|
Pharmaceutical Compositions |
|||
|
Title |
Country |
Application No. (Date) |
Patent No. (Date) |
|
Pharmaceutical Compositions |
US |
15/668,871 (2017.08.04) |
- |
|
JP |
2019-506145 (2017.08.04) |
- |
|
|
EP |
17784385.1 (2017.08.04) |
- |
|
|
CN |
201780049097.7 (2017.08.04) |
- |
|
|
KR |
00-0000-0000000 (2017.08.04) |
|
|
|
CA |
3,030,359 (2017.08.04) |
- |
|
|
AU |
2017307306 (2017.08.04) |
- |
|
|
RU |
2019105698 (2017.08.04) |
- |
|
|
MX |
MX/a/2019/001313 (2017.08.04) |
- |
|
|
BR |
1120190023712 (2017.08.04) |
- |
|
|
IN |
201817050111 (2017.08.04) |
- |
|
|
Priority Date: 2016.08.05 |
|||
|
Title |
Country |
Application No. (Date) |
Patent No. (Date) |
|
Intranasal Delivery Devices for High-Volume Production |
US |
62/563,244 (2017.09.26, provisional) |
|
|
US |
16/137,852 (2018.09.21) |
|
|
|
The Territory |
PCT/JP2018/035560 (2018.09.26) and its national applications claiming priority to PCT/JP2018/035560 in the Field and the Territory |
|
|
|
Priority Date: 2017.09.26 |
|||
|
Medicinal Composition for Nasal Administration |
|||
|
Title |
Country |
Application No. (Date) |
Patent No. (Date) |
|
Medicinal Composition for Nasal Administration |
JP |
2002-2201 (2002.01.09) |
4212019 (2008.11.07) |
|
Priority Date: 2002.01.09 |
|||
|
Compositions for Nasal Administration of Pharmaceuticals |
|||
|
Title |
Country |
Application No. (Date) |
Patent No. (Date) |
|
Compositions for Nasal Administration of Pharmaceuticals |
US |
12/346,537 (2008.12.30) |
8,435,554 (2013.05.07) |
|
|
US |
13/827,859 (2013.03.14) |
9,138,410 (2015.09.22) |
|
|
|
Priority Date: 2003.02.21 |
|
|
• |
Any Patents claiming any Invention(s) disclosed under the SNBL invention disclosure dated November 14, 2016.] |
Page 3of 4
US-DOCS\116938752.2
|
|
2. |
Miscellaneous. Capitalized terms used herein and not otherwise defined shall have the meaning given to them in the Agreement. This Amendment No.4 will be effective for all purposes as of the Amendment No.4 Effective Date. This Amendment No.4 may be executed in two counterparts, including by facsimile or electronically transmitted copies, each of which will be deemed to be an original, but all of which together will constitute one and the same instrument. |
IN WITNESS WHEREOF, the Parties have caused this Amendment No.4 to be signed by their respective duly authorized representatives as of the Amendment No.4 Effective Date.
|
|
Shin Nippon Biomedical Laboratories, Ltd. |
||||||||||
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
||||
|
By: |
/s/ Xxxx Xxxxxxx |
|
|
By: |
/s/ Xxxxxx Xxxxxx |
|
|
||||
|
|
|
|
|
|
|||||||
|
Printed Name: |
Xxxx Xxxxxxx |
|
Printed Name: |
Xxxxxx Xxxxxx |
|||||||
|
|
|
|
|
|
|||||||
|
Title: |
President & CEO |
|
Title: |
TR Company Vice President |
|||||||
Page 4of 4
US-DOCS\116938752.2
